Literature DB >> 19802997

The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

S M Harding1, A J Monro, J E Thornton, J Ayrton, M I Hogg.   

Abstract

The pharmacokinetic behaviour of two aminothiazolyl cephalosporins, ceftazidime (CAZ) and cefotaxime (CTX), were compared in three studies. Doses of each antibiotic were given intravenously (500 mg, n=4; 1 g, n=4) or intramuscularly (1 g, n=8) in a cross-over manner to healthy male volunteers. Antibiotic assays were performed by HPLC and microbiological assay techniques. Both antibiotics appeared to fit a two-compartment iv kinetic model with terminal half-lives of 1.7 h (CAZ) and 0.8 h (CTX). CAZ was metabolically stable whereas there was 34% conversion of CTX to desacetyl-CTX. The 24 h urinary recovery of CAZ averaged 89% but only 51% for CTX. The protein binding of CAZ was 17% and of CTX was 47%. CTX was more painful than CAZ on im injection in seven of the eight volunteers. CAZ therefore appeared to possess a number of features more favourable than those of CTX, when assessed in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 19802997     DOI: 10.1093/jac/8.suppl_b.263

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis.

Authors:  A Hedman; Y Adan-Abdi; G Alvan; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

2.  Comparative activity in vitro of ceftazidime and nine other antibacterial agents.

Authors:  D S Reeves; H A Holt; M J Bywater
Journal:  Infection       Date:  1983       Impact factor: 3.553

Review 3.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 4.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Pharmacokinetics of ceftazidime in patients with biliary tract disease.

Authors:  R A Walstad; J N Wiig; E Thurmann-Nielsen; T B Halvorsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  The in vitro activity of ceftazidime against resistant clinical isolates.

Authors:  H W Van Landuyt; B L Denolf; M Pyckavet; A M Lambert
Journal:  Infection       Date:  1983       Impact factor: 3.553

8.  Ceftazidime, ceftizoxime, cefotaxime and HR 221 in experimental chronic Escherichia coli pyelonephritis in rats.

Authors:  R Marre; D Herhahn; E Schulz; H Freiesleben; K Sack
Journal:  Infection       Date:  1983       Impact factor: 3.553

9.  In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.

Authors:  J A Hoogkamp-Korstanje; C A Meijer
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

10.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.